Shire continues to grow. Our proven business model helps us to deliver on our mission of enabling people with life-altering conditions to lead better lives, through leading the way in our chosen specialist areas.
We have a balanced portfolio of differentiated products that have many years of growth still ahead, as well as the potential to expand into further geographies and markets. Our pipeline is strong and well focused, offering potential drivers of future growth for our portfolio.
Patients are at the heart of our business and we are increasingly engaging with a broader range of stakeholders to ensure that we develop innovative products that payors and policymakers around the world will welcome, as they deliver value to the healthcare system.
Our 5,000 plus employees in 29 countries are united by our distinctive culture that brings the needs of our patients to the fore; everyone at Shire aims to be as brave as the people we help. Through focusing on our patients’ needs, we strive to meet the needs of all our stakeholders.
Total revenues up 23% to
Product sales up 26% to
Non GAAP diluted earnings per ADS
Those of us monitoring the global economy throughout 2011 saw many forces at play. On the one hand, recessionary headwinds, aging populations, the growing prevalence of chronic disease, and the resultant cost of funding new medicines and technologies pressured already strained healthcare budgets and payors…
Throughout 2011 at Shire, we were thinking about value. About how to do more in challenging times. About understanding the complex and interwoven needs of patients, physicians, payors, and policymakers. We recognize that patients’ lives improve only when we understand not just them, but the entire web of care...
Another strong year for Shire with revenues exceeding $4 billion for the first time and Non GAAP diluted earnings per ADS up 26% to $5.34.